Novartis (NVS)
(Delayed Data from NYSE)
$105.67 USD
-0.78 (-0.73%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $105.69 +0.02 (0.02%) 7:18 PM ET
2-Buy of 5 2
A Value C Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$105.67 USD
-0.78 (-0.73%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $105.69 +0.02 (0.02%) 7:18 PM ET
2-Buy of 5 2
A Value C Growth C Momentum A VGM
Zacks News
2 Marijuana Stocks to Buy Heading into Q2 Earnings and Beyond
by Mitchell Moore
The marijuana industry is projected to grow at an annual rate of about 17% until it reaches $55.8 billion a year in 2025. The cannabis market has roughly tracked the S&P 500' s expansion in 2019 so far.
Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold
by Zacks Equity Research
Mallinckrodt (MNK) beats on earnings in Q2 but marginally misses on revenues. The company suspends plan to spin-off the generic business for now.
Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies
by Zacks Equity Research
Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.
Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates
by Zacks Equity Research
Aduro (ADRO) suffers wider-than-expected loss in the second quarter while revenues match estimates.
Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger
by Kinjel Shah
AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.
United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.
Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.
Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised
by Zacks Equity Research
Gilead (GILD) beats on Q2 earnings and sales on solid performance of the HIV franchise. The company also raises its sales guidance for the year.
Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Incyte (INCY) reports better-than-expected results for the second quarter of 2019, owing to strong Jakafi sales.
Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up
by Zacks Equity Research
Eli Lilly's (LLY) Q2 earnings beat estimates while sales miss. New drugs drive sales despite generic competition to key drug Cialis.
Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.
Are Investors Undervaluing Novartis (NVS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bayer (BAYRY) Q2 Earnings Match Estimates, Sales Up Y/Y
by Zacks Equity Research
Bayer (BAYRY) reports in-line earnings in the second quarter of 2019.
Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings?
by Zacks Equity Research
Investors will primarily focus on Jakafi sales and pipeline updates, when Incyte (INCY) reports second-quarter 2019 results.
The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
Top Research Reports for Abbott, Netflix & Philip Morris
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Netflix (NFLX) and Philip Morris (PM).
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines segment is likely to witness sales growth in the second quarter.
Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance
by Zacks Equity Research
Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.
Why Earnings Season Could Be Great for Novartis (NVS)
by Zacks Equity Research
Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Merck's Antibiotic Recarbrio Gets FDA Nod for Infections
by Zacks Equity Research
The FDA approves Merck's (MRK) anti-bacterial injection, MK-7655A, to be marketed as Recarbrio.
Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel
by Zacks Equity Research
Mallinckrodt (MNK) halts its phase IIB study, assessing the efficacy and safety of Acthar Gel as an investigational treatment for amyotrophic lateral sclerosis.
Should You Pick Up Novartis (NVS) Before Q2 Earnings?
by Mitchell Moore
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.
Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?
by Ekta Bagri
Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.
Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA for crizanlizumab and grants Priority Review to the same to prevent pain crises in patients with sickle cell disease.